Treatment with the ATX-specific inhibitor PF-8380 decreases cell migration and invasion in vivo and abrogates radiation-induced cancer neovascularization, suggesting that the inhibition of ATX may ameliorate the GBM response to radiotherapy [77,78]. This evidence concerns the gene ENPP2 and glioblastoma.